{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Safety+in+Healthy+Adults&page=19",
    "query": {
      "condition": "Safety in Healthy Adults",
      "page": 19
    },
    "page_size": 10
  },
  "pagination": {
    "page": 19,
    "page_size": 10,
    "total_count": 1450,
    "total_pages": 145,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Safety+in+Healthy+Adults&page=20&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Safety+in+Healthy+Adults&page=18&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-30T15:22:37.579Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01942265",
      "title": "H7N9 Mix and Match With AS03 and MF59 in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "AS03",
          "type": "DRUG"
        },
        {
          "name": "MF59",
          "type": "DRUG"
        },
        {
          "name": "Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "19 Years to 64 Years"
      },
      "enrollment_count": 980,
      "start_date": "2013-09",
      "completion_date": "2015-01",
      "has_results": false,
      "last_update_posted_date": "2017-07-06",
      "last_synced_at": "2026-10-30T15:22:37.579Z",
      "location_count": 5,
      "location_summary": "Baltimore, Maryland • St Louis, Missouri • Nashville, Tennessee + 2 more",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01942265"
    },
    {
      "nct_id": "NCT00454909",
      "title": "Immunogenicity and Safety of Meningococcal Vaccine GSK134612 vs. Menactra® in Healthy Adolescent/Adults Aged 10-25 Years.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Infections, Meningococcal"
      ],
      "interventions": [
        {
          "name": "Meningococcal vaccine 134612",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Menactra®",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "10 Years to 25 Years"
      },
      "enrollment_count": 873,
      "start_date": "2007-04-23",
      "completion_date": "2008-04-11",
      "has_results": true,
      "last_update_posted_date": "2018-06-08",
      "last_synced_at": "2026-10-30T15:22:37.579Z",
      "location_count": 10,
      "location_summary": "Daly City, California • Fairfield, California • Redwood City, California + 6 more",
      "locations": [
        {
          "city": "Daly City",
          "state": "California"
        },
        {
          "city": "Fairfield",
          "state": "California"
        },
        {
          "city": "Redwood City",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Vallejo",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00454909"
    },
    {
      "nct_id": "NCT01140672",
      "title": "A Multiple Dose Study To Determine Safety, Tolerability, and Pharmacokinetics Of PF-04634817 In Healthy Adult Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "PF-04634817",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 48,
      "start_date": "2010-06",
      "completion_date": "2010-10",
      "has_results": false,
      "last_update_posted_date": "2011-06-08",
      "last_synced_at": "2026-10-30T15:22:37.579Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01140672"
    },
    {
      "nct_id": "NCT01877395",
      "title": "Study of Purified Vero Rabies Vaccine and Rabies Human Diploid Cell Vaccine in a Simulated Rabies Post-exposure Regimen",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Rabies"
      ],
      "interventions": [
        {
          "name": "Purified Vero Rabies Vaccine (VRVg)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Imovax® Rabies: inactivated rabies vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sanofi Pasteur, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 342,
      "start_date": "2013-06",
      "completion_date": "2014-09",
      "has_results": false,
      "last_update_posted_date": "2014-12-03",
      "last_synced_at": "2026-10-30T15:22:37.579Z",
      "location_count": 5,
      "location_summary": "Pembroke Pines, Florida • South Miami, Florida • Boise, Idaho + 2 more",
      "locations": [
        {
          "city": "Pembroke Pines",
          "state": "Florida"
        },
        {
          "city": "South Miami",
          "state": "Florida"
        },
        {
          "city": "Boise",
          "state": "Idaho"
        },
        {
          "city": "Raleigh",
          "state": "North Carolina"
        },
        {
          "city": "West Jordan",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01877395"
    },
    {
      "nct_id": "NCT00574600",
      "title": "Safety of and Immune Response to Two HIV Vaccines: SAAVI DNA-C2 Boosted With SAAVIMVA-C, in HIV-Negative Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "SAAVI DNA-C2 vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "SAAVI MVA-C vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 48,
      "start_date": "2008-11",
      "completion_date": "2013-01",
      "has_results": false,
      "last_update_posted_date": "2021-10-14",
      "last_synced_at": "2026-10-30T15:22:37.579Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00574600"
    },
    {
      "nct_id": "NCT01067781",
      "title": "Safety and Immunogenicity Study of Traveler's Diarrhea Vaccine Patch",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diarrhea"
      ],
      "interventions": [
        {
          "name": "Heat-Labile Enterotoxin of E. coli (LT)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Intercell USA, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 600,
      "start_date": "2010-02",
      "completion_date": "2012-03",
      "has_results": true,
      "last_update_posted_date": "2020-02-10",
      "last_synced_at": "2026-10-30T15:22:37.579Z",
      "location_count": 5,
      "location_summary": "Anaheim, California • South Miami, Florida • Lenexa, Kansas + 2 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "South Miami",
          "state": "Florida"
        },
        {
          "city": "Lenexa",
          "state": "Kansas"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01067781"
    },
    {
      "nct_id": "NCT01573312",
      "title": "H5N1 Vaccination With and Without AS03: Systems Biology Analysis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "ASO3 Adjuvant",
          "type": "DRUG"
        },
        {
          "name": "Influenza A/H5N1 Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 20,
      "start_date": "2012-05-24",
      "completion_date": "2014-01-02",
      "has_results": false,
      "last_update_posted_date": "2019-10-21",
      "last_synced_at": "2026-10-30T15:22:37.579Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01573312"
    },
    {
      "nct_id": "NCT06673667",
      "title": "First-in-human Study of Orally Administered KT-621 in Healthy Adult Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Participants Study"
      ],
      "interventions": [
        {
          "name": "KT-621",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kymera Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "19 Years to 55 Years"
      },
      "enrollment_count": 118,
      "start_date": "2024-10-22",
      "completion_date": "2025-04-23",
      "has_results": false,
      "last_update_posted_date": "2025-10-02",
      "last_synced_at": "2026-10-30T15:22:37.579Z",
      "location_count": 2,
      "location_summary": "Phoenix, Arizona • Lincoln, Nebraska",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Lincoln",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06673667"
    },
    {
      "nct_id": "NCT01965600",
      "title": "A Study To Evaluate The Safety And Effects On The Body Of An Investigational Drug Using An Endotoxin-Induced Inflammatory Response Model",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "PF-06282999",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "LPS",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Years to 40 Years"
      },
      "enrollment_count": 23,
      "start_date": "2014-03",
      "completion_date": "2015-02",
      "has_results": true,
      "last_update_posted_date": "2016-08-02",
      "last_synced_at": "2026-10-30T15:22:37.579Z",
      "location_count": 2,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01965600"
    },
    {
      "nct_id": "NCT04084769",
      "title": "Study to Evaluate the Immune Response After a Booster Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine When Administered Alone or Concomitantly With a Licensed Meningococcal Serogroup B Vaccine, in Participants Who Received Primary Quadrivalent Meningococcal Conjugate Vaccine (MCV4)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Meningococcal Immunisation (Healthy Volunteers)"
      ],
      "interventions": [
        {
          "name": "Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid Conjugate vaccine MenACYW Conjugate vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Meningococcal Group B vaccine (Trumenba®)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Meningococcal group B vaccine (Bexsero®)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sanofi Pasteur, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": "26 Years",
        "sex": "ALL",
        "summary": "13 Years to 26 Years"
      },
      "enrollment_count": 570,
      "start_date": "2019-09-03",
      "completion_date": "2020-09-14",
      "has_results": true,
      "last_update_posted_date": "2025-09-15",
      "last_synced_at": "2026-10-30T15:22:37.579Z",
      "location_count": 29,
      "location_summary": "Birmingham, Alabama • San Diego, California • Bardstown, Kentucky + 20 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Bardstown",
          "state": "Kentucky"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "Bridgeton",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04084769"
    }
  ]
}